Business Context and Reporting Period
This Form 8-K was filed by Inogen, Inc. on January 9, 2017. The report addresses the estimated impact of the 21st Century Cures Act on the company's fourth quarter 2016 financial results and announces upcoming investor conference presentations.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing the estimated financial impact of the 21st Century Cures Act, but the numerical data is not included in the body of this report.
Material Changes
The primary material change disclosed is the estimated impact of the 21st Century Cures Act on Q4 2016 results. No specific quantitative changes versus prior periods are detailed in the text of this filing.
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure: Inogen officers are scheduled to present at the J.P. Morgan 35th Annual Healthcare Conference on January 10, 2017, and the 19th Annual Needham Growth Conference on January 12, 2017.
- Updated Materials: An updated slide presentation (Exhibit 99.2) will be used during these sessions and is incorporated by reference.
- Webcast: Live audio webcasts for both conferences are available via the Investor Relations section of the company website.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific numerical estimates regarding the 21st Century Cures Act impact on Q4 2016.
- Access Exhibit 99.2 (Investor Presentation) for updated operational and financial outlooks.
- Verify the timing and content of the J.P. Morgan and Needham Growth Conference presentations.